Last reviewed · How we verify

NCT05711225

Transtheoretic Model, Postpartum Smoking Relapse, Smoking Cessation Intervention

Completed NA Last updated 2 February 2023
What this trial tests

NA trial testing smoking cessation intervention given according to the web-based transtheoretic model during pregnancy on postpartum smoking relapse. in Postpartum Smoking Relapse in 70 participants. Completed in 1 December 2022.

Timeline
24 March 2021
Primary endpoint
1 May 2022
1 December 2022

Quick facts

Lead sponsorSemra YILMAZ
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposehealth services research
Enrollment70
Start date24 March 2021
Primary completion1 May 2022
Estimated completion1 December 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Semra YILMAZ

Who can join

Eligibility, female only, with Postpartum Smoking Relapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The postpartum period is an important opportunity to improve maternal and fetal health by preventing smoking relapse in women. To achieve this goal, digital platforms, which are the latest technological developments are used. However, studies using digital platforms on smoking cessation and postpartum smoking relapse in pregnant women are limited in this area. The research was carried out to determine the effect of smoking cessation intervention prepared in line with the transtheoretic model on the digital platform, on preventing smoking relapse in the postpartum period. As a result of the research, it is thought that nurses will guide their professional practices with an evidence-based up-to-date approach.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Postpartum Smoking Relapse

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05711225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing